Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats

Journal of Musculoskeletal Neuronal Interactions

Volumn 4, Issue 1, 2004, Pages 22-32

  Li, Mei ^a   Healy, D R ^a   Li, Y ^a   Simmons, H A ^a   Su, M ^b   Jee, W S S ^b   Shen, V W ^c   Thompson, D D ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c SkeleTech Inc   (United States)

Author keywords

Alfacalcidol; Bone formation; Bone mass; Bone resorption; Bone strength

Indexed keywords

ALFACALCIDOL; COTTON SEED OIL; FLUOROCHROME; TESTOSTERONE;

AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; BONE TISSUE; BONE TURNOVER; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; DOSE RESPONSE; DRUG EFFECT; FLUOROCHROME STAINING; LUMBAR VERTEBRA; MALE; MECHANICAL STRESS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PERIOSTEUM; RAT; TESTOSTERONE BLOOD LEVEL; TIBIA; TRABECULAR BONE;

AGING; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYCHOLECALCIFEROLS; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS; OSTEOPOROSIS; PERIOSTEUM; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE; TIBIA; UP-REGULATION; WEIGHT-BEARING;

EID: 2642529643     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Aloia, JF, Vaswani A, Yeh JF. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988; 84:401-408.
2. Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Pro Soc Exp Biol Med 1989; 191:287-292.
3. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990; 113:649-655.
4. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326:357-362.
5. Sairanen S, Kärkkäinen M, Tähtelä R, Laitinen K, Mäkelä P, Lamberg-Allardt C, Välimäki MJ. Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25-Dihydroxyvitamin D (Calcitriol) for four years. Calcif Tissue Int 2000; 67:122-127.
6. 3. Bone Miner 1992; 20:223-234.
7. 3. Bone Miner 1987; 3:47-52.
8. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54:370-376.
9. Ringe JD, Cöster A, Meng T, Schacht E, Umback R. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999; 65:337-340.
10. Martin TJ, Raisz LG, Rodan G. Calcium regulation and bone metabolism. In: Martin TJ, Raisz LG (eds) Clinical Endocrinology of Calcium Metabolism. Marcel Dekker, New York; 1987:1-52.
11. Holtrop ME, Cox KA, Clark MB, Holick MF, Anast CS. 1,25-dihydroxycholecalciferol stimulates osteocalsts in rat bones in the absence of parathyroid hormone. Endocrinol 1981; 108:2293-2301.
12. 3-treated rats fed high levels of dietary calcium. Bone 1985; 6:105-112.
13. Raisz LG, Trummel CL, Holik MF, DeLuca HF. 1,25-dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture. Science 1972; 175:768-769.
14. 3 on bone of thyroparathyroidectomized rats fed a low-calcium diet. Am J Pathol 1978; 92:459-472.
15. Suda T, Takahashi N, Abe E. Role of vitamin D in bone resorption. J Cell Biochem 1992; 49:53-58.
16. Takeda S, Yoshizwa T, Naagai Y, Yamato H, Fukumoto S, Sekine K, Kato S, Matsumoto T, Fujita T. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinol 1999; 140:1005-1008.
17. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320:980-991.
18. 3 receptor-like macromolecule in rat osteogenic sarcoma cell lines. J Biol Chem 1980; 225:4414-4417.
19. 3 in bones from fetal rats. Calcif Tissue Int 1983; 35:177-182.
20. Kato S, Takeyama K, Kitanaka S, Murayama A, Sekine K, Yoshizawa T. In vivo function of VDR in gene expression-VDR knock-out mice. J Steroid Biochem Mol Biol 1999; 69:247-251.
21. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinol 1998, 139:4391-4396.
22. 3. Biochem 1988; 27:8521-8526.
23. 3 on gene transcription. J Biol Chem 1989; 264:2279-2282.
24. 3 stimulates the synthesis of matrix-carboxy-glutamic acid protein by osteosarcoma cells. J Biol Chem 1988; 263:911-916.
25. Prince CW, Butler WT. 1,25-dihydroxyvitamin D regulates the biosynthesis of osteopontin, a bone-derived, cell attachment protein. Collagen Rel Res 1987; 7:305-313.
26. Noda M, Yoon K, Prince CW, Butler WT, Rodan GA. Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type β transforming growth factor. J Biol Chem 1988; 263:13916-13921.
27. Franceschi RT, James WM, Zerlauth G. 1α,25-dihydroxyvitamin D sepecific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line. J Cell Physiol 1985; 123:401-409.
28. 3 on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem 1982; 257:3362-3365.
29. 3 increases bone alkaline phosphatase enzyme levels in human osteogenic sarcoma cell. J Biol Chem 1983; 258:6219-6225.
30. 3 and human bone-derived cells in vitro: effects on alkaline phosphatase, type I collagen and proliferation. Endocrinol 1986; 119:1776-1785.
31. 3 analogs and dexamethasone on the expression of osteocalcin gene in rat tibiae in vivo. Biochem Biophys Res Commun 1992; 189:1231-1235.
32. 3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinol 1997; 138:4629-4635.
33. Erben RG, Weiser H, Sinowatz F, Rambeck WA, Zucker H. Vitamin D metabolites prevent vertebral osteopenia in ovariectomized rats. Calcif Tissue Int 1992; 50:228-236.
34. 3 on bone. Endocrinol 1998; 139:4319-4328.
35. 3 on ovariectomy-induced cancellous bone loss in the rat. Calcif Tissue Int 1997; 60:434-440.
36. Faugere M-C, Okamoto S, DeLuca HF, Malluche HH. Calcitriol corrects bone loss induced by oophorectomy in rats. Endocrinol Metab 1986; 13:E35-E38.
37. Shiraishi A, Takeda A, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000; 15:770-779.
38. Shiraishi A, Higashi S, Masaki T, Ito M, Ikeda S, Nakamura T. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 2002; 71:69-79.
39. Nishikawa T, Ogawa S, Kogita K, Manabe N, Katsumata T, Nakamura K, Kawaguchi H. Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 2000; 27:647-64.
40. Li M, Li Y, Healy DR, Simmons HA, Ke HZ, Thompson DD. Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskel Neuron Interact 2003; 3(1):39-46.
41. Baron R, Vignery A, Neff L, Silvergate A, Santa Maria A. Processing of undecalcified bone specimens for bone histomorphometry. In: Recker RR (ed) Bone Histomorphometry: Techniques and Interpretation. CRC Press, Boca Raton, FL; 1983:13-35.
42. Erben RG. Trabecular and endocortical bone surfaces in the rat: modeling and remodeling? Anat Rec 1996; 246:39-46.
43. Parfitt AM, Mathews CHE, Villaneuva AR, Kleerekoper M, Frame B, Rao DS. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 1983; 72:1396-1409.
44. Frost HM. Bone histomorphometry: Analysis of trabecular bone dynamics. In: Recker RR (ed) Bone Histomorphometry: Techniques and interpretation. CRC Press, Boca Raton, FL; 1983:109-131.
45. Villanueva AR. A bone stain for osteoid seams in fresh unembedded, mineralized bone. Stain Technol 1974; 49:1-8.
46. Jee WSS, Li XJ, Inoue J, Jee KW, Haba T, Ke HZ, Setterberg RB, Ma YF. Histomorphometric assay of the growing bone. In: Takahashi HE (ed) Handbook of bone morphology 2nd ed. Nishimura, Niigata, Japan; 1997:87-112.
47. 2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia. Bone 1998; 23:249-255.
48. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lcay DL, Dunstan CR. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinol 2001; 1426:4295-4303.
49. Li M, Jee WSS, Ke HZ, Tang LY, Ma YF, Liang XG, Setterberg RB. Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats. J Bone Miner Res 1995; 10:66-73.
50. Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res 2000; 15:1085-1098.
51. Ke HZ, Crawford DT, Qi H, Chidsey-Frink KL, Simmons HA, Li M, Jee WSS, Thompson DD. Long-term effects of aging and orchidectomy on bone and body composition in rapidly growing male rats. J Musculoskel Neuron Interact 2001; 1:215-224.
52. 3. J Bone Miner Res 2002; 17:1498-1511.
53. 3 corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. Endocrinol 1988; 122:1998-2006.
54. 3. Calcif Tissue Int 1992; 50:221-227.
55. Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinol 2002; 143:1625-1636.
56. 3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 1994; 54:142-149.
57. Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Kishii Y. Effects of a synthetic vitamin D analog, ED-71, on bone dynamic and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 1996; 11:325-33.
58. Kubodera N, Tsuji N, Uchiyama Y, Endo K. A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem 2003; 88:286-289.
59. Erben RG, Kohn B, Weiser H, Sinowatz F, Rambeck WA. Role of vitamin D metabolites in the prevention of the osteopenia induced by ovariectomy in the axial and appendicular skeleton of the rat. Z Ernährungswiss 1990; 29:229-248.
60. Erben RG. Vitamin D analogs and bone. J Musculoskel Neuron Interact 2001; 2(1):59-69.
61. Frost HM. Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff's law: The modeling problem. Anat Rec 1990; 226:403-413.
62. Kobayashi S, Takahashi HE, Ito A, Saito N, Nawata M, Horiuchi H, Ohta H, Ito A, Iorio R, Yamamoto N, Takaoka K. Trabecular minimodeling in human iliac bone. Bone 2003; 32:163-169.